TheCannalysts Podcast featuring Blue, Molly, and Cyto.
Inside the Ropes: Extraction Special with Tom Ulanowski
We talk to our special guest Tom Ulanowski, Quality Assurance Person (QAP) at NextLeaf Labs, about all things extraction. We cover the basics of extraction, differences in extraction methods, product formats, economics of scaling, biomass inputs and much more!
Inside the Ropes: Episode 37
We discuss Auxley's latest quarter, Aurora's recent guidance and satisfying lenders, High Tide and Meta merger and Village Farms taking over their join venture. We also go over Supreme and 1933 industries reprice and raises, the CPG buzzword and Cronos replacing their CEO.
Inside the Ropes Episode 36 featuring Nick Nedin
We start by reading an e-mail GoBlue received from Investor relations of Liberty Health Sciences. Follow up with quarterlies of Canopy, Tilray, Aleafia, Trulieve, Green Thumb, Village Farms, LABS, Sundial. Cyto then goes over patience with R&D, promises and covering your bases.
Finally we bring in Nick Nedin from the Flower Hour Podcast to talk about distribution and brand building.
Inside the Ropes Episode 35
We go over the quarterlies of OGI, Valens, Aphria, LHS. What to look for in upcoming quarters regarding shipment versus retail sales disparities, Canopy, Tilray, Cronos and Aurora.
We also talk about:
Cannabis safety validation and Mushroom stocks
Provincial/State Fiefdoms by necessity
Watch for companies to pivot
Pharma and pharma-lite companies, how they compare
Inside the Ropes Episode 34
We talk about the quarterlies of Acreage, Heritage and Liberty Health. Also go over Canopy's repricing of Acreage, the Outdoor Harvest Tsunami and C21 Investments CEO's story.
Inside the Ropes Episode 33
We talk about LABS Quarterly and what it means for other extractors, followed by: HEXO, Sundial, FAF, HITI and ISH quarterlies.
Also discuss Zena's zombie raise and the potential for other zombie raises, Acerage’s $15MM 60% annual interest loan.
Continue with Extractors:
Will RTI continue to pay for all their expenses in shares.
Will CANN blow off the fact that Cronos vapes are not selling as anticipated.